April 27, 2020 / 10:07 PM / a month ago

BRIEF-Magforce AG Received FDA Approval To Proceed With Next Stage Of Study For Ablation Of Prostate Cancer With Nanotherm Therapy

April 27 (Reuters) - Magforce AG:

* DGAP-ADHOC: MAGFORCE AG: MAGFORCE USA, INC. HAS RECEIVED FDA APPROVAL TO PROCEED WITH ITS STREAMLINED TRIAL PROTOCOL FOR THE NEXT STAGE OF PIVOTAL U.S. SINGLE-ARM STUDY FOR THE FOCAL ABLATION OF INTERMEDIATE RISK PROSTATE CANCER WITH THE NANOTHERM THERAPY

* MAGFORCE - STILL HOPEFUL THAT COVID-19 PANDEMIC WILL NOT CAUSE SIGNIFICANT DELAY BEYOND 2020 TO COMPLETE THIS SINGLE-ARM CLINICAL TRIAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below